

## THURSDAY, 19 MAY 2016

### 08.30 – 10.45 Session 1

08.30 Emerging insights into the immunopathophysiology of MS  
*Roland Liblau (Toulouse, FR)*

09.15 Brain of MS patient: MRI, PET, clinical manifestation  
*Igor Stolyarov (St. Petersburg, RU)*

10.00 Cognitive impairment in MS  
*Maria Pia Amato (Florence, IT)*

### 10.45 – 11.15 Coffee Break

### 11.15 - 13.30 Session 2

11.15 Modern diagnostic work-up of patients suspected of MS and clinical phenotypes  
*Tobias Derfus (Basel, CH)*

12.00 Mechanism of action of therapeutic monoclonal antibodies  
*Alexey Boyko (Moscow, RU)*

12.45 Mechanism of action of oral therapies  
*Roland Liblau (Toulouse, FR)*

## FRIDAY, 20 MAY 2016

**08.30 – 10.45** **Workshop 1:** When and how to start therapy. Should all CIS patients and RIS patients be treated?  
*Finn Sellebjerg (Copenhagen, DK)*

**Workshop 2:** Escalating or switching therapy. Treat to NEDA 2, 3 or 4?  
*Per Soelberg Sørensen (Copenhagen, DK)*

**Workshop 3:** Monitoring therapy and adherence to therapy  
*Tobias Derfuss (Basel, CH)*

*Each workshop will take place 08.30-09.15; 09.15-10.00; 10.00-10.45*

### 10.45 – 11.15 Coffee Break

### 11.15 – 13.30 Session 3

11.15 Risk stratification and mitigation considerations with new MS therapies  
*Per Soelberg Sørensen (Copenhagen, DK)*

12.00 Place of haematological and mesenchymal stem cell treatment in MS  
*Nikolaos Grigoriadis (Thessaloniki, GR)*

12.45 Current treatment algorithm and future changes  
*Xavier Montalban (Barcelona, ES)*